Cumulative response by phase on third-line TKI
| Response . | Dasatinib, no. (%) . | Nilotinib, no. (%) . | Overall, no. (%) . |
|---|---|---|---|
| Chronic phase | n = 16 | n = 9 | n = 25 |
| Hematologic | |||
| CHR | 13 (81) | 6 (67) | 19 (76) |
| Cytogenetic | |||
| mCyR | 4 (25) | 2 (22) | 6 (24) |
| CCyR | 5 (31) | 1 (11) | 6 (24) |
| PCyR | 1 (6) | 1 (11) | 2 (8) |
| Molecular | |||
| MMR | 2 (13) | 3 (33) | 5 (20) |
| Accelerated phase | n = 8 | n = 2 | n = 10 |
| Hematologic | |||
| CHR | 7 (88) | 2 (100) | 9 (90) |
| Cytogenetic | |||
| mCyR | 1 (13) | 0 (0) | 1 (10) |
| CCyR | 2 (25) | 0 (0) | 2 (20) |
| PCyR | 1 (13) | 1 (50) | 2 (20) |
| Molecular | |||
| MMR | 1 (13) | 0 (0) | 1 (10) |
| Blast phase | n = 10 | n = 3 | n = 13 |
| Hematologic | |||
| CHR/RCP | 4 (40) | 2 (67) | 6 (46) |
| Cytogenetic | |||
| mCyR | 1 (10) | 1 (33) | 2 (15) |
| CCyR | 2 (20) | 1 (33) | 3 (23) |
| PCyR | 1 (10) | 0 (0) | 1 (8) |
| Molecular | |||
| MMR | 1 (10) | 0 (0) | 1 (8) |
| Response . | Dasatinib, no. (%) . | Nilotinib, no. (%) . | Overall, no. (%) . |
|---|---|---|---|
| Chronic phase | n = 16 | n = 9 | n = 25 |
| Hematologic | |||
| CHR | 13 (81) | 6 (67) | 19 (76) |
| Cytogenetic | |||
| mCyR | 4 (25) | 2 (22) | 6 (24) |
| CCyR | 5 (31) | 1 (11) | 6 (24) |
| PCyR | 1 (6) | 1 (11) | 2 (8) |
| Molecular | |||
| MMR | 2 (13) | 3 (33) | 5 (20) |
| Accelerated phase | n = 8 | n = 2 | n = 10 |
| Hematologic | |||
| CHR | 7 (88) | 2 (100) | 9 (90) |
| Cytogenetic | |||
| mCyR | 1 (13) | 0 (0) | 1 (10) |
| CCyR | 2 (25) | 0 (0) | 2 (20) |
| PCyR | 1 (13) | 1 (50) | 2 (20) |
| Molecular | |||
| MMR | 1 (13) | 0 (0) | 1 (10) |
| Blast phase | n = 10 | n = 3 | n = 13 |
| Hematologic | |||
| CHR/RCP | 4 (40) | 2 (67) | 6 (46) |
| Cytogenetic | |||
| mCyR | 1 (10) | 1 (33) | 2 (15) |
| CCyR | 2 (20) | 1 (33) | 3 (23) |
| PCyR | 1 (10) | 0 (0) | 1 (8) |
| Molecular | |||
| MMR | 1 (10) | 0 (0) | 1 (8) |
If the same patient achieved both a MMR and CCyR, it was recorded for both responses in the table.